Mechanism of Action
TRH Receptor Subtypes
TRH binds two Gq-coupled receptor subtypes: TRH-R1 (pituitary and limbic system) and TRH-R2 (brainstem and spinal cord). Both receptors activate PLC, generating IP3 and DAG, which increase intracellular calcium and activate PKC. Pituitary TRH-R1 activation releases TSH and prolactin. CNS TRH-R2 activation modulates arousal circuits, noradrenergic and dopaminergic neurotransmission, and produces the neuroprotective effects independent of pituitary signaling.
Neuroprotective and Analeptic Actions
TRH acts as a physiological antagonist to CNS depressants including ethanol, barbiturates, and opioids through brainstem receptor activation. Central TRH stimulates norepinephrine and dopamine release, increases respiratory drive, elevates blood pressure, and reverses coma in animal models. These properties, combined with anti-apoptotic signaling in neurons, form the basis for neuroprotective and injury-recovery research.
Research Summary
Spinal Cord Injury
HumanSmall Phase II trials showed IV TRH administered within hours of spinal cord injury improved motor and sensory function recovery. The peptide attenuates secondary injury mechanisms including lipid peroxidation and edema. Larger confirmatory trials were not completed, leaving evidence preliminary but encouraging.
Depression and Mood
HumanSeveral controlled trials showed rapid antidepressant effects from a single IV TRH dose, with improvement visible within 6-24 hours. Effects were brief (days) with native TRH due to its short half-life. These findings preceded the ketamine antidepressant discoveries and established the concept of rapid-acting antidepressants.
ALS and Neurodegenerative Disease
HumanSpinal intrathecal TRH improved motor function transiently in ALS patients in small trials. Regular IV TRH administration modestly slowed functional decline in some studies. The need for parenteral delivery and short duration of effect limited clinical adoption.
Calculate your TRH dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antidepressant research | 500 mcg, 1 mg | Single IV dose | Intravenous |
| Neuroprotection / spinal injury | 0.2-0.8 mg/kg | Single acute dose or short course | IV or intrathecal |
| Intranasal CNS delivery | 2-5 mg | Variable | Intranasal |
Short plasma half-life limits duration of effects. Intranasal delivery bypasses the pituitary and peripheral metabolism, targeting CNS receptors more directly.
Interactions
Safety Profile
TRH has a long clinical safety record as a pituitary diagnostic agent. IV injection produces transient nausea, flushing, urinary urgency, and mild hypertension lasting minutes, consistent with pituitary TSH and prolactin release. Thyroid effects are minimal at single diagnostic doses. Prolonged use could suppress thyroid axis via feedback. TRH is an endogenous hypothalamic peptide with a naturally established physiological role.
References
- [1]Guillemin R, Burgus R. The hormones of the hypothalamus. Sci Am. 1972;227(5):24-33.
- [2]Callaway CW, et al. Thyrotropin-releasing hormone reverses the effects of ethanol in rats. Science. 1982.
- [3]Soblosky JS, et al. Systemic thyrotropin-releasing hormone improves neurological outcome after acute cervical spinal cord injury. J Neurotrauma. 1992.